Mesoblast received FDA clearance for a registrational DMD trial of remestemcel-L-rknd, while Satellos began dosing boys in the Phase 2 BASECAMP study of SAT-3247. The studies are enrolling children ages 5-9 and 7-9, respectively.
Precision BioSciences receives FDA Fast Track designation for PBGENE-DMD, a gene editing therapy for Duchenne muscular dystrophy designed to treat patients with mutations in exons 45-55.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07609394 |
Duchenne Electronic Health Record Study |
RECRUITING | |
| NCT02069756 |
The Duchenne Registry |
RECRUITING |
